Number of suitable people: CDEC reviewed the uncertainty in the quantity of sufferers with moderately serious to severe hemophilia B in Canada suitable for etranacogene dezaparvovec. Medical authorities consulted by CADTH indicated that some individuals who are categorised as possessing mild or average ailment could have a serious bleeding phenotype, https://hemgenix49264.blogdosaga.com/35676202/everything-about-hemgenix